Gyre Therapeutics (GYRE) News Today $8.98 -0.02 (-0.22%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period GNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in ChinaJune 11 at 3:17 AM | msn.comGyre Therapeutics Inc.: Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaJune 10 at 11:42 AM | finanznachrichten.deGyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaJune 10 at 7:00 AM | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Sees Large Volume Increase - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Sees Strong Trading Volume - Time to Buy?June 3, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Down 7.9% - What's Next?Gyre Therapeutics (NASDAQ:GYRE) Trading Down 7.9% - Here's WhyJune 3, 2025 | marketbeat.comGyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis TrialsMay 31, 2025 | finance.yahoo.comGyre Therapeutics, Inc. (GYRE) Raises $23M in Public Stock Offering to Fund Liver Fibrosis TrialsMay 30, 2025 | msn.comGyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 29, 2025 | finance.yahoo.comInsider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of StockGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $10.97, for a total value of $21,940.00. Following the sale, the president now owns 2,808,824 shares of the company's stock, valued at approximately $30,812,799.28. This trade represents a 0.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.May 29, 2025 | marketbeat.comGyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesMay 29, 2025 | globenewswire.comGyre Therapeutics (NASDAQ:GYRE) Sees Strong Trading Volume - Should You Buy?Gyre Therapeutics (NASDAQ:GYRE) Sees Large Volume Increase - Here's WhyMay 29, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - What's Next?Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - Should You Buy?May 28, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Down - What's Next?Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down - Here's What HappenedMay 25, 2025 | marketbeat.comGyre Therapeutics launches public stock offeringMay 24, 2025 | investing.comGyre Therapeutics announces new stock offeringMay 24, 2025 | uk.investing.comGyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB ...May 24, 2025 | morningstar.comGyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in Liver Fibrosis Treatment, Paving Way for NDA Submission in 2025May 24, 2025 | nasdaq.comGyre Therapeutics Announces Commencement of Underwritten Public Offering of Common StockMay 24, 2025 | nasdaq.comGyre Therapeutics Shares Fall as Stock Offering Overshadows Positive Trial DataMay 23, 2025 | marketwatch.comGyre Therapeutics Announces Proposed Underwritten Public Offering of Common StockMay 23, 2025 | finance.yahoo.comGyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common StockMay 23, 2025 | finance.yahoo.comGyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common StockMay 22, 2025 | globenewswire.comGyre Therapeutics Announces Proposed Underwritten Public Offering of Common StockMay 22, 2025 | globenewswire.comGyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in ChinaMay 22, 2025 | globenewswire.comMajor Exercise Alert: Weiguo Ye Exercises Options Worth $478K At Gyre TherapeuticsMay 15, 2025 | benzinga.comGyre Therapeutics (NASDAQ:GYRE) Trading 14.3% Higher - Still a Buy?Gyre Therapeutics (NASDAQ:GYRE) Trading 14.3% Higher - Here's What HappenedMay 14, 2025 | marketbeat.comGyre Therapeutics First Quarter 2025 Earnings: EPS: US$0.031 (vs US$0.09 in 1Q 2024)May 10, 2025 | finance.yahoo.comGyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | globenewswire.comA Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To EquityMay 7, 2025 | finance.yahoo.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 5.9% - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 5.9% - Here's WhyMay 7, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Hits New 12-Month High - Still a Buy?Gyre Therapeutics (NASDAQ:GYRE) Sets New 12-Month High - Here's WhyMay 3, 2025 | marketbeat.comGyre Therapeutics (GYRE) to Release Quarterly Earnings on ThursdayGyre Therapeutics (NASDAQ:GYRE) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-gyre-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Up 5% - Time to Buy?Gyre Therapeutics (NASDAQ:GYRE) Trading 5% Higher - Should You Buy?April 30, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Up 4.7% - Time to Buy?Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 4.7% - Here's What HappenedApril 17, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Hits New 12-Month Low - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Reaches New 12-Month Low - Here's WhyApril 12, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 11.9% - What's Next?Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 11.9% - Here's What HappenedApril 11, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Up 13.3% - Here's What HappenedGyre Therapeutics (NASDAQ:GYRE) Shares Up 13.3% - Here's What HappenedApril 10, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 10.5% - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Trading Up 10.5% - Should You Buy?April 4, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Hits New 1-Year Low - What's Next?April 2, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Down 12.5% - Time to Sell?Gyre Therapeutics (NASDAQ:GYRE) Shares Down 12.5% - What's Next?April 1, 2025 | marketbeat.comGyre Therapeutics announces NMPA approval for trial on pirfenidoneMarch 31, 2025 | markets.businessinsider.comGyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary ComplicationsMarch 31, 2025 | globenewswire.comGyre Therapeutics announces publication of protocol for Phase 3 trial on F351March 27, 2025 | markets.businessinsider.comWe Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) EarningsMarch 27, 2025 | finance.yahoo.comGyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational HepatologyMarch 27, 2025 | globenewswire.comGyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $20,260.00 in StockGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $10.13, for a total transaction of $20,260.00. Following the completion of the transaction, the president now directly owns 2,827,018 shares of the company's stock, valued at approximately $28,637,692.34. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.March 22, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.7% - Time to Sell?Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.7% - What's Next?March 22, 2025 | marketbeat.comGyre: Intriguing Upcoming Data Catalyst, But I'm Still On SidelinesMarch 21, 2025 | seekingalpha.comGyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 SharesGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $12.09, for a total value of $24,180.00. Following the sale, the president now directly owns 2,829,260 shares of the company's stock, valued at $34,205,753.40. This represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 20, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Up 10.5% - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Shares Up 10.5% - What's Next?March 20, 2025 | marketbeat.com Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address GYRE Media Mentions By Week GYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GYRE News Sentiment▼0.621.01▲Average Medical News Sentiment GYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GYRE Articles This Week▼42▲GYRE Articles Average Week Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MorphoSys News Today Kymera Therapeutics News Today Scholar Rock News Today MoonLake Immunotherapeutics News Today Immunovant News Today Lyell Immunopharma News Today Apellis Pharmaceuticals News Today Organon & Co. News Today HUTCHMED News Today ImmunityBio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GYRE) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GYRE Stock Free GYRE Stock Alerts